These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 24295492)

  • 21. MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
    Matamala N; Vargas MT; González-Cámpora R; Arias JI; Menéndez P; Andrés-León E; Yanowsky K; Llaneza-Folgueras A; Miñambres R; Martínez-Delgado B; Benítez J
    Oncotarget; 2016 Apr; 7(15):20068-79. PubMed ID: 26933805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of epigenetic modifications in luminal breast cancer.
    Abdel-Hafiz HA; Horwitz KB
    Epigenomics; 2015 Aug; 7(5):847-62. PubMed ID: 25689414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic utility of epigenetics in breast cancer - A review.
    Bhat SA; Majid S; Wani HA; Rashid S
    Cancer Treat Res Commun; 2019; 19():100125. PubMed ID: 30802811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1.
    Coyle KM; Murphy JP; Vidovic D; Vaghar-Kashani A; Dean CA; Sultan M; Clements D; Wallace M; Thomas ML; Hundert A; Giacomantonio CA; Helyer L; Gujar SA; Lee PW; Weaver IC; Marcato P
    Oncotarget; 2016 Jul; 7(28):44096-44112. PubMed ID: 27286452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
    Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment.
    Basse C; Arock M
    Int J Cancer; 2015 Dec; 137(12):2785-94. PubMed ID: 25410431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.
    Yan M; Shield-Artin K; Byrne D; Deb S; Waddell N; ; Haviv I; Fox SB
    BMC Cancer; 2015 Jul; 15():506. PubMed ID: 26152113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miRNA dysregulation in breast cancer.
    Mulrane L; McGee SF; Gallagher WM; O'Connor DP
    Cancer Res; 2013 Nov; 73(22):6554-62. PubMed ID: 24204025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA signatures in hereditary breast cancer.
    Murria Estal R; Palanca Suela S; de Juan Jiménez I; Egoavil Rojas C; García-Casado Z; Juan Fita MJ; Sánchez Heras AB; Segura Huerta A; Chirivella González I; Sánchez-Izquierdo D; Llop García M; Barragán González E; Bolufer Gilabert P
    Breast Cancer Res Treat; 2013 Nov; 142(1):19-30. PubMed ID: 24129975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA in breast cancer: The association with BRCA1/2.
    Petrovic N; Davidovic R; Bajic V; Obradovic M; Isenovic RE
    Cancer Biomark; 2017; 19(2):119-128. PubMed ID: 28128741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer.
    Kagara N; Huynh KT; Kuo C; Okano H; Sim MS; Elashoff D; Chong K; Giuliano AE; Hoon DS
    Am J Pathol; 2012 Jul; 181(1):257-67. PubMed ID: 22626806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deconstructing the molecular portrait of basal-like breast cancer.
    Yehiely F; Moyano JV; Evans JR; Nielsen TO; Cryns VL
    Trends Mol Med; 2006 Nov; 12(11):537-44. PubMed ID: 17011236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer.
    Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Gruvberger-Saal SK; Saal LH; Holm K; Hegardt C; Arason A; Fagerholm R; Persson C; Grabau D; Johnsson E; Lövgren K; Magnusson L; Heikkilä P; Agnarsson BA; Johannsson OT; Malmström P; Fernö M; Olsson H; Loman N; Nevanlinna H; Barkardottir RB; Borg Å
    Cancer Res; 2012 Aug; 72(16):4028-36. PubMed ID: 22706203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic and epigenetic characterization of the BRCA1 gene in Brazilian women at-risk for hereditary breast cancer.
    Felicio PS; Melendez ME; Arantes LM; Kerr LM; Carraro DM; Grasel RS; Campacci N; Scapulatempo-Neto C; Fernandes GC; de Carvalho AC; Palmero EI
    Oncotarget; 2017 Jan; 8(2):2850-2862. PubMed ID: 27926510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic changes in BRCA1-mutated familial breast cancer.
    Downs B; Wang SM
    Cancer Genet; 2015 May; 208(5):237-40. PubMed ID: 25800897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic control of phospholipase A2 receptor expression in mammary cancer cells.
    Menschikowski M; Hagelgans A; Nacke B; Jandeck C; Sukocheva O; Siegert G
    BMC Cancer; 2015 Dec; 15():971. PubMed ID: 26672991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment.
    Dworkin AM; Huang TH; Toland AE
    Semin Cancer Biol; 2009 Jun; 19(3):165-71. PubMed ID: 19429480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genome-wide analysis of DNA methylation and expression of microRNAs in breast cancer cells.
    Morita S; Takahashi RU; Yamashita R; Toyoda A; Horii T; Kimura M; Fujiyama A; Nakai K; Tajima S; Matoba R; Ochiya T; Hatada I
    Int J Mol Sci; 2012; 13(7):8259-8272. PubMed ID: 22942701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salivary gland-like tumors of the breast express basal-type immunohistochemical markers.
    Reyes C; Jorda M; Gomez-Fernández C
    Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):283-6. PubMed ID: 22935826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.